Lipid-modified muc-1 derivatives
AssigneeBiomira, Inc.
InventorsBabita Agrawal, Mark J. Krantz, Mark A. Reddish, B. Michael Longenecker
Life of this patent
Estimating the term…
Abstract
A method for generating a mixture of activated T-cells by combining a plurality of peripheral blood lymphocytes (PBLs) with an antigen-loaded liposome to produce antigen-loaded PBLs, and combining the antigen-loaded PBLs with a naive, anergic or memory T-cell, to produce an activated T-cell. Such activation is carried out in vivo or in vitro. The antigen-loaded PBLs and activated T-cells, prepared according to the methods of invention, have use as cellular vaccines for treatment of cancer and viral diseases.
Claims16
A MUC-1 peptide that is covalently modified with a lipid moiety, wherein said MUC-1 peptide generates an antigen-specific T-cell response and comprises a sequence of from about 7 to about 20 amino acids of the sequence STAPPAHGVTSAPDTRAPGSTAPP (SEQ ID NO. 5).
A MUC-1 peptide that is covalently modified with a lipid moiety, wherein said MUC-1 peptide generates an antigen-specific T-cell response and consists essentially of a sequence of from about 7 to about 20 amino acids of the sequence TAPPAHGVTSAPDTRAPGSTAPP (SEQ ID NO. 23).
Dependencies are inferred from the claim text.